Knoa Pharma Begins Operations as a New, Public Health-Focused Company Dedicated to Supporting Patients and Abating the Opioid Crisis
Knoa Pharma LLC (“Knoa Pharma”) today begins operations as an independent company created to ensure safe access to medicines that are critical to patient care and to support communities with a purpose dedicated to abating the opioid crisis and improving public health. The company emerged following the conclusion of Purdue Pharma L.P.’s Chapter 11 proceedings on May 1, 2026, at which time Purdue permanently ceased operations. Established with the key stakeholders and creditor constituencies, including the United States Department of Justice, the States, Territories and other governmental entities, personal injury victims, and other stakeholders, Knoa Pharma was designed with strong governance, clear accountability, and a commitment to serving the public good.
